An acute phase protein ready to go therapeutic for sepsis

The so-called Acute Phase Response (APR) begins between 12 and 48 h after the initiation of inflammation. This conserved response mainly involves the production of a set of Acute Phase Proteins (APPs) and the downregulation of other proteins (negative APPs) by hepatocytes. Although the precise ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandevyver, Sofie, Dejager, Lien, Vandenbroucke, Roosmarijn E, Libert, Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell 2014
Materias:
Closeup
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936485/
https://www.ncbi.nlm.nih.gov/pubmed/24408964
http://dx.doi.org/10.1002/emmm.201303524
_version_ 1782305313402126336
author Vandevyver, Sofie
Dejager, Lien
Vandenbroucke, Roosmarijn E
Libert, Claude
author_facet Vandevyver, Sofie
Dejager, Lien
Vandenbroucke, Roosmarijn E
Libert, Claude
author_sort Vandevyver, Sofie
collection PubMed
description The so-called Acute Phase Response (APR) begins between 12 and 48 h after the initiation of inflammation. This conserved response mainly involves the production of a set of Acute Phase Proteins (APPs) and the downregulation of other proteins (negative APPs) by hepatocytes. Although the precise identity of the APPs may differ between species, some APPs are common in all mammals.
format Online
Article
Text
id pubmed-3936485
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Blackwell
record_format MEDLINE/PubMed
spelling pubmed-39364852014-03-07 An acute phase protein ready to go therapeutic for sepsis Vandevyver, Sofie Dejager, Lien Vandenbroucke, Roosmarijn E Libert, Claude EMBO Mol Med Closeup The so-called Acute Phase Response (APR) begins between 12 and 48 h after the initiation of inflammation. This conserved response mainly involves the production of a set of Acute Phase Proteins (APPs) and the downregulation of other proteins (negative APPs) by hepatocytes. Although the precise identity of the APPs may differ between species, some APPs are common in all mammals. Blackwell 2014-01 2014-01-09 /pmc/articles/PMC3936485/ /pubmed/24408964 http://dx.doi.org/10.1002/emmm.201303524 Text en © 2014 The Authors. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, 1 which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Closeup
Vandevyver, Sofie
Dejager, Lien
Vandenbroucke, Roosmarijn E
Libert, Claude
An acute phase protein ready to go therapeutic for sepsis
title An acute phase protein ready to go therapeutic for sepsis
title_full An acute phase protein ready to go therapeutic for sepsis
title_fullStr An acute phase protein ready to go therapeutic for sepsis
title_full_unstemmed An acute phase protein ready to go therapeutic for sepsis
title_short An acute phase protein ready to go therapeutic for sepsis
title_sort acute phase protein ready to go therapeutic for sepsis
topic Closeup
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936485/
https://www.ncbi.nlm.nih.gov/pubmed/24408964
http://dx.doi.org/10.1002/emmm.201303524
work_keys_str_mv AT vandevyversofie anacutephaseproteinreadytogotherapeuticforsepsis
AT dejagerlien anacutephaseproteinreadytogotherapeuticforsepsis
AT vandenbrouckeroosmarijne anacutephaseproteinreadytogotherapeuticforsepsis
AT libertclaude anacutephaseproteinreadytogotherapeuticforsepsis
AT vandevyversofie acutephaseproteinreadytogotherapeuticforsepsis
AT dejagerlien acutephaseproteinreadytogotherapeuticforsepsis
AT vandenbrouckeroosmarijne acutephaseproteinreadytogotherapeuticforsepsis
AT libertclaude acutephaseproteinreadytogotherapeuticforsepsis

Ejemplares similares